190 related articles for article (PubMed ID: 20826559)
21. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
Granville CA; Memmott RM; Gills JJ; Dennis PA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):679-89. PubMed ID: 16467077
[TBL] [Abstract][Full Text] [Related]
22. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
23. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
24. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract][Full Text] [Related]
25. Nutritional control of cell growth via TOR signaling in budding yeast.
Wei Y; Zheng XF
Methods Mol Biol; 2011; 759():307-19. PubMed ID: 21863495
[TBL] [Abstract][Full Text] [Related]
26. [TOR-centric concept of regulation mitogenic, metabolic and energetic signal processing in cell].
Zubova SG; Shitikova ZhV; Pospelova TV
Tsitologiia; 2012; 54(8):589-602. PubMed ID: 23074850
[TBL] [Abstract][Full Text] [Related]
27. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation.
Nagai S; Kurebayashi Y; Koyasu S
Ann N Y Acad Sci; 2013 Mar; 1280():30-4. PubMed ID: 23551100
[TBL] [Abstract][Full Text] [Related]
28. Targeting the mTOR Pathway in Leukemia.
Dinner S; Platanias LC
J Cell Biochem; 2016 Aug; 117(8):1745-52. PubMed ID: 27018341
[TBL] [Abstract][Full Text] [Related]
29. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.
Janes MR; Fruman DA
Methods Mol Biol; 2012; 821():251-65. PubMed ID: 22125070
[TBL] [Abstract][Full Text] [Related]
30. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Hauge M; Bruserud Ø; Hatfield KJ
Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
[TBL] [Abstract][Full Text] [Related]
31. Evolutionarily conserved regulation of TOR signalling.
Takahara T; Maeda T
J Biochem; 2013 Jul; 154(1):1-10. PubMed ID: 23698095
[TBL] [Abstract][Full Text] [Related]
32. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Tarantelli C; Lupia A; Stathis A; Bertoni F
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033478
[TBL] [Abstract][Full Text] [Related]
33. PI3K pathway inhibitors approach junction.
Holmes D
Nat Rev Drug Discov; 2011 Aug; 10(8):563-4. PubMed ID: 21804582
[No Abstract] [Full Text] [Related]
34. TOR complex 2: a signaling pathway of its own.
Cybulski N; Hall MN
Trends Biochem Sci; 2009 Dec; 34(12):620-7. PubMed ID: 19875293
[TBL] [Abstract][Full Text] [Related]
35. Amino acid signaling in TOR activation.
Kim J; Guan KL
Annu Rev Biochem; 2011; 80():1001-32. PubMed ID: 21548787
[TBL] [Abstract][Full Text] [Related]
36. A longer and healthier life with TOR down-regulation: genetics and drugs.
Bjedov I; Partridge L
Biochem Soc Trans; 2011 Apr; 39(2):460-5. PubMed ID: 21428920
[TBL] [Abstract][Full Text] [Related]
37. [m-TOR inhibitors: biology and use in the treatment of haematological diseases].
Balsat M; Cornillon J
Bull Cancer; 2011 Aug; 98(8):935-43. PubMed ID: 21827982
[TBL] [Abstract][Full Text] [Related]
38. mTOR Signalling in Health and Disease.
Proud CG
Biochem Soc Trans; 2011 Apr; 39(2):431-6. PubMed ID: 21428914
[TBL] [Abstract][Full Text] [Related]
39. Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.
Abohassan M; Alshahrani M; Alshahrani MY; Rajagopalan P
Med Oncol; 2022 Oct; 39(12):249. PubMed ID: 36209300
[TBL] [Abstract][Full Text] [Related]
40. LST8 regulates cell growth via target-of-rapamycin complex 2 (TORC2).
Wang T; Blumhagen R; Lao U; Kuo Y; Edgar BA
Mol Cell Biol; 2012 Jun; 32(12):2203-13. PubMed ID: 22493059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
